Clinical Trial Detail

NCT ID NCT02537418
Title Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors NCIC Clinical Trials Group
Indications

Advanced Solid Tumor

lung small cell carcinoma

Therapies

Cisplatin + Etoposide

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.